We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Jul 2020 - 30 Jul 2020

Immature Natural Killer Cells Predict Relapse After Cord Blood Transplantation

By LabMedica International staff writers
Posted on 31 Dec 2019
Print article
Image: Schematic diagram of how novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation (CBT) (Photo courtesy of MD Anderson Cancer Center).
Image: Schematic diagram of how novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation (CBT) (Photo courtesy of MD Anderson Cancer Center).
Umbilical cord blood transplantation (CBT) has become an accepted alternative treatment of patients with hematologic cancers or other disorders. Many of the disadvantages of CBT, including limited numbers of total nucleated cells, have been dealt with in significant ways, leading to marked reductions in the time to hematopoietic cell recovery.

Natural killer (NK) cells are highly heterogeneous, with vast phenotypic and functional diversity at the single-cell level. They are involved in the innate immune response against malignant and virus-infected cells. Although the kinetics of T- and B-cell subset recovery after CBT are well-described, much less is known about the recovery of CB-derived natural killer (NK) cells in the post-transplant setting.

Stem transplantation specialists at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) used high-dimensional mass cytometry and the metrics of NK cell diversity to study the NK cell repertoire in serial samples from 43 CBT recipients. A panel comprising 40 metal-tagged antibodies was used for the detailed characterization of NK cells. To assess NK cell cytotoxicity, the team co-cultured NK cells with 51Cr-labeled K562 targets at multiple E:T ratios (20:1, 10:1, 5:1, 1:1); cytotoxicity was measured by target release of 51Cr.

Total RNA was collected from five million NK cells per donor and pooled libraries were sequenced (50-bp paired-end reads generated with the HiSeq 2500 (Illumina, San Diego, CA, USA). Data were acquired on a Helios mass cytometer (Fluidigm, South San Francisco, CA, USA) and fluorescence cytometry data were acquired on BD LSRFortessa X-20 (BD Biosciences, San Jose, CA, USA).

The investigators reported that a higher-diversity index based on single-cell combinatorial phenotypes was significantly associated with a lower risk for relapse after CBT. Cytomegalovirus reactivation was a major factor in the development of a more diverse NK repertoire after CBT. They identified a group of patients whose CB-derived NK cells after transplantation possessed an immature phenotype (CB-NKim), characterized by poor effector function and a low diversity index. Frequencies of CB-NKim of 11.8% or higher during the early post-CBT recovery phase were highly predictive for relapse, a finding that was validated in a second independent cohort of 25 patients. They also showed that the maturation, diversity, and acquisition of effector function by CB-NKim early after CBT were driven by interleukin 15.

The authors concluded that their data indicated that the diversity of the NK cell repertoire after CBT contributes importantly to the risk for subsequent relapse. They suggest that the use of diversity metrics and high-dimensional mass cytometry may be useful tools in predicting clinical outcomes and informing the design of therapeutic strategies to prevent relapse after CBT. The study was published on December 10, 2019 in the journal Blood Advances.

Related Links:
The University of Texas MD Anderson Cancer Center
BD Biosciences

Print article



view channel
Image: The Idylla system is a fully-automated, real-time polymerase chain reaction (PCR) based molecular testing system designed to offer results in a minimal amount of time (Photo courtesy of Biocartis).

Rapid Genomic Profiling of Colon Cancers Improves Therapy Selection

Colorectal cancer is a malignant tumor arising from the inner wall of the large intestine (colon) or rectum. Colorectal cancer is the third leading cause of cancer in both men and women in the USA.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.